Navigation Links
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Date:8/4/2011

DANBURY, Conn., Aug. 4, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the third quarter ended June 30, 2011.

Third Quarter Operating Highlights

During Biodel's third quarter of fiscal year 2011, the company:

  • completed Phase 1 testing of two new ultra-rapid-acting formulations of recombinant human insulin, or RHI, for subcutaneous injection;
  • supported investigators at Oregon Health and Sciences University who have initiated a Phase 1 study evaluating these formulations for insulin pump administration;
  • selected multiple analog-based candidate formulations for possible clinical development; and
  • extended the cash runway by reducing near-term RHI purchase requirements and raising approximately $30 million in new capital.

  • Dr. Errol De Souza, president and chief executive officer of Biodel, stated:  "We are continuing to develop and evaluate ultra-rapid-acting human insulin and insulin analog formulations and are making good progress in assessing tolerability and activity in a variety of pre-clinical and clinical settings.  We plan to provide details on the pharmacokinetic, pharmacodynamic and injection site tolerability characteristics of the two RHI-based ultra-rapid-acting formulations from the recently completed subcutaneous injection Phase 1 trial and will update the timelines for completion of the insulin pump trial.  In addition, we have taken a number of steps to extend our cash runway including renegotiation of our RHI supply agreement and raising additional capital from previous and new investors.  These initiatives are helping us create a new generation of ultra-rapid-acting insulin product candidates and sustainable long-term value for all shareholders."

    Third Quarter Financial Results

    Biodel reported a net loss of $4.0 million, or $0.12 per sha
    '/>"/>

    SOURCE Biodel Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
    2. Biodel to Raise $30 Million Through Registered Direct Offering
    3. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
    4. Biodel Announces Name Change for Lead Product Candidate
    5. Dyadic International Reports 2011 Second Quarter Financial Results
    6. Vermillion Reports Results for the Second Quarter 2011
    7. ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports
    8. Dendreon Reports Second Quarter 2011 Financial Results
    9. Cambrex Reports Second Quarter of 2011 Results
    10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
    11. Gen-Probe Reports Financial Results for the Second Quarter of 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
    (Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
    (Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
    (Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
    Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
    ... ONOM@TOPIC and SilOnIS shared the ... most innovative and sustainable project in the ... smartcard platform for,citizenship and mobile multimedia applications ... for users,while adding value for network operators. ...
    ... Investor Update Conference Call Set for March 7, ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,it has entered into ... the privately-held specialty pharmaceuticals marketer which,Senetek licensed in ...
    ... 4 Osteotech, Inc.,(Nasdaq: OSTE ), a ... for,regenerative medicine, announced today that the Food and ... its Plexur,M(TM) Biocomposite. Adapting the Company,s proprietary Plexur(R),Technology, ... bony voids or gaps,of the skeletal system that ...
    Cached Biology Technology:MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3Senetek PLC in Dispute With Marketer of Pyratine-6(TM) 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 2Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite 3
    (Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
    (Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
    (Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
    Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3
    ... University of Nottingham have taken some important first steps ... a leading science journal reports. Dr Cameron Alexander ... of Pharmacy have used polymers long-chain molecules ... surfaces of a real cell. In work published ...
    ... by clean, local-source energy. Faster, more reliable technologies ... language. Medical care tailored to your DNA, or ... diseases and injuries. Five University of Pittsburgh ... health, and technology as part of Faculty Early ...
    ... Researchers from Weill Cornell Medical College may have discovered ... the world,s most common blood disorders, beta-thalassemia, commonly known ... is the most commonly inherited disease in the world, ... of every 100,000 African-Americans. The World Health Organization estimates ...
    Cached Biology News:Life, but not as we know it? 2Pitt faculty receive awards to explore next-generation technologies 2Pitt faculty receive awards to explore next-generation technologies 3Pitt faculty receive awards to explore next-generation technologies 4Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 2Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 3Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf 4
    Protein Marker Detection Pack contains biotinylate...
    This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
    UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
    This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
    Biology Products: